natgillin/translations-raw huggingface dataset:
Mozobil should not be used in people who may be hypersensitive (allergic) to plerixafor or any of the other ingredients.
Zdravila Mozobil ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) pleriksafor ali katero koli drugo sestavino zdravila.
Mozobil was more effective than placebo at mobilising stems cells from the bone marrow into the blood.
Zdravilo Mozobil je bilo pri mobilizaciji matičnih celic iz kostnega mozga v kri učinkovitejše od placeba.
MP Jointsa p-value
MP sklepia p-vrednost
MPA at clinically relevant concentrations is 97% bound to plasma albumin.
V klinično relevantnih koncentracijah je mikofenolna kislina 97 % vezana na plazemske albumine.
MPA’s disposition depends on several transporters.
Razporeditev mikofenolne kisline je odvisna od različnih prenašalcev.
MPR+p vs MPp +p
MPR+p proti MPp +p
MPR+R vs MPp+p
MPR+R proti MPp+p
MPR+R vs MPR+p
MPR+R proti MPR+p
MPS I disease
Mukopolisaharidoza tipa I
MPS I is a heterogeneous and multisystemic disorder characterised by the deficiency of -L-iduronidase, a lysosomal hydrolase which catalyses the hydrolysis of terminal -L-iduronic residues of dermatan sulfate and heparan sulfate.
Mukopolisaharidoza tipa I je heterogena in multisistemska motnja, za katero je značilno pomanjkanje -L-iduronidaze, lizosomske hidrolaze, ki katalizira hidrolizo -L-iduronskih ostankov dermatan sulfata in heparan sulfata.
MPS IVA is characterized by the absence or marked reduction in N-acetylgalactosamine-6-sulfatase activity.
Za MPS IVA sta značilna odsotnost ali bistveno zmanjšanje dejavnosti N-acetilgalaktozamin-6- sulfataze.
MRD negative
MRD negativna
MRD negative****
Negativen MRD
MRD positive
MRD pozitivna
MRD positivef (%)
MRD-pozitivnif (%)
MRD status at end of induction treatment
Status MRD na koncu indukcijskega zdravljenja
MRI (0-2 years)
MRS (0-2 let)
MRI endpoints
Cilji opazovanja pri slikanju z MR
MRI endpoints
Opazovani dogodki na MRS
MRI Endpoints (0-2 years)
Opazovani dogodki na MRS (0-2 leti)
MRI endpoints#
Opazovani dogodki na MR slikanju#
MRI endpoints†
Opazovani dogodki na MR slikanju
MRI Osteitis/Bone Oedema Score
MRI ocena osteitisa/edema kostnine
MRI tumour response was evaluated by RECIST 1.1. Response by digital clinical photograph was evaluated by World Health Organization (WHO) adapted criteria [partial response (PR): ≥50% decrease in the sum of the product of perpendicular diameters (SPD) of a lesion; complete response (CR): disappearance of all lesions; progressive disease: ≥25% increase in the SPD of lesions].
Tumorski odziv na MR posnetkih so ocenjevali po kriterijih RECIST 1.1. Odziv na digitalnih kliničnih fotografijah so ocenjevali po prilagojenih kriterijih Svetovne zdravstvene organizacije [delni odziv (partial response, PR): ≥50-odstotno zmanjšanje vsote produktov dveh pravokotnih premerov posameznih lezij; popoln odziv (complete response, CR): izginotje vseh lezij; napredovanje bolezni: ≥25-odstotno povečanje vsote produktov dveh pravokotnih premerov posameznih lezij].
MRLs
Najvišje
MRP-2, BCRP and OATP1B1/1B3.
MRP-2, BCRP in OATP1B1/1B3.
MS is a disease of the nerves, in which inflammation destroys the protective sheath around the nerves (demyelination).
Multipla skleroza je obolenje živcev, pri katerem vnetje poškoduje zaščitno ovojnico okrog živcev (demielinizacija).
MS is a disease of the nerves, in which inflammation destroys the protective sheath around the nerves.
Multipla skleroza je obolenje živcev, pri kateri vnetje poškoduje zaščitno ovojnico okrog njih.
MS is a disease of the nerves, in which inflammation destroys the protective sheath surrounding the nerve cells.
Multipla skleroza je obolenje živcev, pri kateri vnetje uniči zaščitni ovoj okoli živčnih celic.
MS is a long term illness that affects the central nervous system (CNS), including the brain and spinal cord, in which the body’s immune system (its natural defences) damages the protective layer (myelin) that surrounds the nerves in the brain and spinal cord.
MS je dolgotrajna bolezen, ki prizadene osrednji živčni sistem, vključno z možgani in hrbtenjačo, pri kateri telesni imunski sistem (njegova naravna obramba) poškoduje zaščitno plast (mielin), ki obdaja živce v možganih ali hrbtenjači.
MS pseudo-relapse (frequency not known): There is a possibility that at the beginning of your treatment with Rebif you may experience symptoms that resemble those of a multiple sclerosis relapse.
Navidezni ponovni zagon MS (pogostnost ni znana): Obstaja možnost, da boste na začetku zdravljenja z zdravilom Rebif opazili znake, ki so podobni znakom ponovnega zagona multiple skleroze.
MS relapse, dizziness*, hypoaesthesia, paraesthesia, tremor, dysgeusia*
recidiv MS, omotica*, hipestezija, parestezija, tremor, paragevzija
MS-H Vaccine, like all vaccines, works by ‘teaching’ the immune system (the body’s natural defences) how to defend itself against a disease.
Cepivo MS-H kot vsa druga cepiva deluje tako, da imunski sistem (naravni obrambni mehanizem telesa) „nauči“, kako naj se brani pred boleznijo.
MS-history yrs, median (range)
Zgodovina obolelosti za MS v letih, mediana (razpon)
MSD Pharma Hungary Kft Tel.: +36 1 888
Sanofi Pasteur MSD, Tél: +32.2.726.95.84
MSD Pharma Hungary Kft.
Merck Sharp & Dohme s.r.o.
MSD Polska Sp. z o.o., Tel.: +48.22.549.51.00
Sanofi Pasteur MSD, Sími: +32.2.726.95.84
MSD Polska Sp. z o.o., Tel.: +48.22.549.51.00
UAB Merck Sharp & Dohme Tel.: +370.5.2780.247
MSD Polska Sp. z o.o., Tel: +48.22.549.51.00
Sanofi Pasteur MSD, Sími: +32.2.726.95.84
MSKCC prognostic score (blinded independent central review)
prognostična lestvica MSKCC (slepo neodvisno centralno pregledovanje)
MSWS-12-score (mean, sem) (Multiple Sclerosis Walking Scale)
12-stopenjska lestvica hoje za multiplo sklerozo (SNP)
MTIC is spontaneously hydrolysed to 5-amino-imidazole-4- carboxamide (AIC), a known intermediate in purine and nucleic acid biosynthesis, and to methylhydrazine, which is believed to be the active alkylating species.
4-karboksamida (AIK), znanega intermediata v biosintezi purinov in nukleinskih kislin, in metilhidrazina, za katerega menijo, da je aktivni alkilirajoči presnovek.
MTIC is spontaneously hydrolyzed to 5-amino-imidazole-4- carboxamide (AIC), a known intermediate in purine and nucleic acid biosynthesis, and to methylhydrazine, which is believed to be the active alkylating species.
MTIC se spontano hidrolizira v 5-amino-imidazol-4-karboksamid (AIC), znanega posrednika pri biosintezi purina in nukleinske kisline, in v metilhidrazin, ki je verjetno aktivna alkilirajoča različica.
MTIC is spontaneously hydrolyzed to 5-amino-imidazole-4- carboxamide (AIC), a known intermediate in purine and nucleic acid biosynthesis, and to methylhydrazine, which is believed to be the active alkylating species.
MTIC spontano hidrolizira v 5-amino-imidazol-4-karboksamid (AIC), ki je znan intermediat v biosintezi purinov in nukleinskih kislin, in v metilhidrazin, za katerega se domneva, da je aktivni alkilirajoči presnovek.
MTIC is spontaneously hydrolyzed to 5-amino-imidazole-4- carboxamide (AIC), a known intermediate in purine and nucleic acid biosynthesis, and to methylhydrazine, which is believed to be the active alkylating species.
MTIK pa spontano hidrolizira do 5-amino-imidazol-4- karboksamida (AIK), znanega intermediata v biosintezi purinov in nukleinskih kislin, in metilhidrazina, za katerega menijo, da je aktivni alkilirajoči presnovek.
MTIC is spontaneously hydrolyzed to 5-amino-imidazole-4- carboxamide (AIC), a known intermediate in purine and nucleic acid biosynthesis, and to methylhydrazine, which is believed to be the active alkylating species.
MTIK pa spontano hidrolizira do 5-amino-imidazol-4- karboksamida (AIK), znanega intermediata v biosintezi purinov in nukleinskih kislin, ter metilhidrazina, za katerega menijo, da je aktivni alkilirajoči presnovek.
MTIC is spontaneously hydrolyzed to 5-amino-imidazole-4-carboxamide (AIC), a known intermediate in purine and nucleic acid biosynthesis, and to methylhydrazine, which is believed to be the active alkylating species.
MTIK pa spontano hidrolizira do 5-amino-imidazol- 4- karboksamida (AIK), znanega intermediata v biosintezi purinov in nukleinskih kislin, ter metilhidrazina, za katerega menijo, da je aktivni alkilirajoči presnovek.
MTIC is spontaneously hydrolyzed to 5-amino-imidazole-4-carboxamide (AIC), a known intermediate in purine and nucleic acid biosynthesis, and to methylhydrazine, which is believed to be the active alkylating species.
MTIK pa spontano hidrolizira do 5-amino-imidazol- 4-karboksamida (AIK), znanega intermediata v biosintezi purinov in nukleinskih kislin, ter metilhidrazina, za katerega menijo, da je aktivni alkilirajoči presnovek.
MTP (Microsomal Trigylyceride transfer Protein) inhibitors as a class have the potential to disrupt yolk sac development and laboratory studies on rats and rabbits have shown evidence of embryolethality, teratogenicity, and developmental toxicity.
Laboratorijske raziskave na podganah in kuncih so pokazale, da delujejo teratogeno, povzročijo lahko tudi smrt zarodkov ali motnje v razvoju.
mTSS: modified Total Sharp Score
mTSS: modificirani celotni seštevek po Sharpu
MTX
14,8
MTX
N/A 29,3
MTX (5 g/m2 over 24 hours, IV): day 1
MTX (5 g/m2 v času 24 ur, i.v.): 1. dan
MTX - Methotrexate
MTX - metotreksat
MTX 15mg intrathecal, day 1
MTX 15 mg intratekalno, 1. dan indukcijsko zdravljenje I
MTX 500 mg/m2 i.v. (24 h), days 1, 15;
MTX 500 mg/m2 i.v. (24 ur), 1., 15. dan;
MTX 500 mg/m2 i.v. (24 h), days 1, 15;
MTX 500 mg/m² i.v. (24 ur), 1., 15. dan;
MTX n=257 (95% confidence interval)
MTX n = 257 (95 % interval zaupanja)
MTX n=257 (95% confidence interval)
MTX n = 257 (95% interval zaupanja)
MTX P value
P vrednost
Much of the general pharmacokinetic information was obtained using the Rapamune oral solution, which is summarised first.
Veliko splošnih farmakokinetičnih podatkov je iz študij s peroralno raztopino zdravila Rapamune, zato so ti povzeti najprej.
Muckle-Wells Syndrome (MWS),
Indikacija vključuje naslednje sindrome:
Mucocutaneous reaction (including Stevens Johnson Syndrome) *
mukokutane reakcije (vključno s Stevens Johnsonovim sindromom)
mucolytics and lastly, Cayston.
mukolitiki in nazadnje zdravilo Cayston
Mucosal healing
Celjenje sluznice
Mucosal healing at week 30a
Celjenje sluznice v 30. tednua
Mucosal healing at week 8a
celjenje sluznice v 8. tednua
Mucosal healing¶
Celjenje sluznice¶
Mucosal hyperplasia, with diverticulum/cyst formation was observed in the colon and caecum of mice after 2 years treatment, but this was considered a species-specific effect with no diverticula/cysts seen in long term studies in rats or dogs.
Po 2­letnem zdravljenju so pri miših opazili hiperplazijo sluznice z nastajanjem divertikla/ciste v kolonu in slepem črevesu, a se je to štelo za učinek, specifičen za živalsko vrsto, saj pri dolgoročnih študijah na podganah in psih ni bilo opaziti divertiklov/cist.
Mucosal inflammation
vnetje dojk/mastitis
Mucosal inflammation
vnetje sluznic
mucosal inflammation
vnetje sluznice
Mucosal inflammation Malaise
Bolezni sečil
Mucosal inflammation Malaise
vnetje sluznice splošno slabo počutje
Mucosal inflammation, Pain in limb, Pain, Chills, Chest pain, Influenza-like illness, +Fever, Infusion related reaction, Injection site reaction, Infusion site pain, Injection site pain
podobna gripi, zvišana telesna temperatura, z infuzijo povezana reakcija, reakcija na mestu injiciranja, bolečina na mestu infundiranja, bolečina na mestu injiciranja
Mucosal inflammation, Pain in limb, Pain, Chills, Chest pain, Influenza-like illness, +Fever, Infusion related reaction, Injection site reaction, Infusion site pain, Injection site pain
telesna temperatura, z infuzijo povezana reakcija, reakcija na mestu injiciranja, bolečina na mestu infundiranja, bolečina na mestu injiciranja
Mucosal inflammation, Pain in limb, Pain, Chills, Chest pain, Influenza-like illness, +Fever, Infusion related reaction, Injection site reaction, Infusion site pain, Injection site pain
vnetje sluznic, bolečina v okončinah, bolečina, mrazenje, bolečina v prsnem košu, bolezen podobna gripi, +zvišana
Mucosal inflammation, Pain in limb, Pain, Chills, Chest pain, Influenza-like illness, +Fever, Infusion related reaction, Injection site reaction, Infusion site pain, Injection site pain
vnetje sluznic, bolečina v okončinah, bolečina, mrazenje, bolečina v prsnem košu, bolezen podobna gripi, +zvišana telesna temperatura, z infuzijo povezana reakcija, reakcija na mestu injiciranja, bolečina na mestu infundiranja, bolečina na mestu injiciranja
Mucosal inflammation, Pain in limb, Pain, Chills, Chest pain, Influenza-like illness, +Fever, Infusion related reaction, Injection site reaction, Infusion site pain, Injection site pain
zvišana telesna temperatura, z infuzijo povezana reakcija, reakcija na mestu injiciranja, bolečina na mestu infundiranja, bolečina na mestu injiciranja
Mucosal inflammation, pyrexia, weight decreased, peripheral oedema, chills
vnetje sluznice, pireksija, zmanjšanje telesne mase, periferni edemi, mrzlica
Mucosal inflammationa
bolečine v prsiha
Mucosal inflammationa
utrujenosta vnetje sluznicea
Mucosal inflammatione
vnetje sluznicee
Mucosal ulceration
razjede na sluznici
Mucositis
Vnetje sluznice
Mucositis or Constipation Grade 2  5 days or Grade  3 any duration1
2, ki traja 5 dni ali stopnje 3 ne glede na trajanje1
Mucositis Vomiting Diarrhoea Nausea
Mukozitis Bruhanje Driska Navzeja
Mucositis/ stomatitis
Mukozitis / stomatitis
Mucositis/ Stomatitis
Mukozitis/ Stomatitis
Mucositis/ stomatitis
Mukozitis/S tomatitis
Mucositis/ stomatitis
Mukozitis/St omatitis
Mucositis/ stomatitis
Mukozitis/Sto matitis
Mucositis/mucosal inflammation
mukozitis/vnetje sluznic bolečina
Mucous membrane disorder
Spremembe na sluznici
Muenchen Bayern, 85748 Germany
Muenchen Bayern, 85748 Nemčija
Mulhuddart, Dublin 15, Ireland.
Mulhuddart Dublin 15 Irska
MULTAQ 400 mg film-coated tablets
MULTAQ 400 mg filmsko obložene tablete
MULTAQ does not usually affect your ability to drive or use machine.
Zdravilo MULTAQ navadno ne vpliva na sposobnost upravljanja vozil in strojev.
MULTAQ has no or negligible influence on the ability to drive and use machines.
Zdravilo MULTAQ nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
MULTAQ interacts with a number of medicines; if they consult other doctors they should inform them that they are taking MULTAQ; they should not take St John’s Wort with MULTAQ; they should avoid grapefruit juice.
e morajo posvetovati z zdravnikom, če imajo kratko sapo ali neproduktiven kašelj; zdravilo MULTAQ medsebojno deluje s številnimi zdravili; v primeru posveta pri drugih zdravnikih le-tem povedo, da jemljejo zdravilo MULTAQ; skupaj z zdravilom MULTAQ ne smejo uporabljati šentjanževke; se morajo izogibati grenivkinemu soku.
Multaq is a medicine that contains the active substance dronedarone.
Multaq je zdravilo, ki vsebuje zdravilno učinkovino dronedaron.
MULTAQ is a white, oval, film-coated tablet (tablet) with a double wave marking on one side and “4142” on the other side.
Tablete MULTAQ so bele, ovalne filmsko obložene tablete z oznako dvojnega vala na eni strani in kodo "4142" na drugi strani.
MULTAQ is contraindicated in patients with severe hepatic impairment because of the absence of data (see section 4.3 and 4.4).
MULTAQ je zaradi pomanjkanja podatkov kontraindiciran pri bolnikih s hudo okvaro jeter (glejte poglavje in 4.4).
MULTAQ is contraindicated in patients with severe renal impairment (creatinine clearance (CrCl) <30 ml/min) (see section 4.3).
MULTAQ je kontraindiciran pri bolnikih s hudo okvaro ledvic (očistek kreatinina < 30 ml/min (glejte poglavje 4.3).
MULTAQ is not recommended if you are pregnant or you think you may be pregnant.
Uporaba zdravila MULTAQ ni priporočljiva, če ste noseči ali domnevate, da ste noseči.
MULTAQ is not recommended in children and adolescents below 18 years of age.
Zdravilo MULTAQ ni priporočljivo za otroke in mladostnike, mlajše od 18 let.
MULTAQ is used if you have a problem with your heart beat (your heart beats out of time - atrial fibrillation) and a treatment called cardioversion has changed your heartbeat back to normal rhythm.
Zdravilo MULTAQ se uporablja, če imate moteno bitje srca (srce vam bije neredno – atrijska fibrilacija) in je zdravljenje, ki ga imenujemo kardioverzija, vaš srčni utrip znova vrnilo v normalen ritem.
Multaq is used to maintain normal heart rhythm in adults with types of non-permanent atrial fibrillation known as ‘persistent’ or ‘paroxysmal’ after normal heart rhythm has been restored.
Zdravilo Multaq se uporablja za vzdrževanje normalnega srčnega ritma pri odraslih s „trdovratno“ ali
Multaq must not be used in patients who have severe problems with their liver or kidneys.
Zdravila ne smejo jemati bolniki, ki imajo huda obolenja jeter ali ledvic.
Multaq must not be used in people who are hypersensitive (allergic) to the active substance or any of the other ingredients.
Zdravila Multaq ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) zdravilno učinkovino ali katero koli drugo sestavino zdravila.
MULTAQ prevents repetition of your problem of irregular heart beat.
Zdravilo MULTAQ prepreči ponovitev težav z nerednim bitjem srca.
Multaq should not be given to patients with left ventricular systolic dysfunction (a problem affecting the left side of the heart) or patients who have or have had heart failure (when the heart cannot pump enough blood around the body).
Zdravilo Multaq se ne sme dajati bolnikom s sistolično disfunkcijo levega prekata (obolenjem, ki prizadene levo stran srca) ali bolnikom, ki imajo ali so imeli srčno popuščanje (kadar srce ne more načrpati dovolj krvi po telesu).
Multaq should only be prescribed after alternative treatment options have been considered.
Zdravilo Multaq se lahko predpiše šele, ko so že bile proučene druge možnosti zdravljenja.
Multaq was more effective than placebo at preventing atrial fibrillation from reoccurring.
Zdravilo Multaq je bilo pri preprečevanju ponovne atrijske fibrilacije učinkovitejše od placeba.
Multaq was originally approved to prevent atrial fibrillation from coming back or to lower the heart rate in adults who have had or have non-permanent atrial fibrillation.
Zdravilo Multaq je bilo prvotno odobreno za preprečevanje ponovitve atrijske fibrilacije ali zniževanje srčnega utripa pri odraslih, ki so imeli ali imajo nepermanentno atrijsko fibrilacijo.
multi organ dysfunction, reaction related to infusion of the medicine change in hair colour
nepravilno delovanje več organov, reakcije, povezane z infundiranjem zdravila sprememba barve las
multi organ inflammation
vnetje več organov
Multi pack of 5 packs of 10 pre-filled syringes without needle.
5 setov s po 10 napolnjenimi injekcijskimi brizgami brez igel.
Multi-dose amber glass vial containing 20 ml solution for injection, closed with a rubber stopper and sealed with an aluminium cap.
Večodmerna viala iz temnega stekla vsebuje 20 ml raztopine za injiciranje in je zaprta z gumijastim zamaškom in aluminijasto zaporko.
Multi-dose amber-coloured glass injection vials closed with rubber stopper and sealed with an aluminium crimped top.
Večodmerna viala jantarne barve z gumijastim pokrovčkom in aluminijasto zaporko.
MULTI-DOSE CONTAINER
NALEPKA NA VEČODMERNEM VSEBNIKU
Multi-dose container (PP)
Večodmerni vsebnik s črpalko
Multi-dose container composed of two extruded parts, one external white polypropylene rigid tube and one internal (ethylene-methacrylic acid)-zinc copolymer (Surlyn) flexible pouch containing a steel ball, closed with a 1 ml dosing airless pump equipped with a flexible atraumatic cannula and covered by a plastic cap.
Večodmerni vsebnik, sestavljen iz dveh ekstrudiranih delov, in sicer zunanje bele polipropilenske trdne stekleničke in notranje gibljive vrečke iz (etilen-metakrilno kislinskega) – cinkovega kopolimera (surlyn) in z jekleno kroglico, ki se zapira z enomililitrsko odmerno brezzračno črpalko z gibljivo atravmatsko kanilo in je pokrita s plastičnim pokrovčkom.
Multi-dose vial
Plastenka s 50 odmerki
Multi-dose vial
Večodmerne plastenke
Multi-organ failure
odpoved več organov,
multi-organ failure death.
odpoved več organov smrt.
Multi-organ failure Pain
odpoved več organov bolečine
Multi-organ failure, performance status decreased, pain, oedema, chest pain, chest discomfort, generalized oedema, face oedema, local swelling, localized oedema, weight increased, early satiety, feeling cold, injection site reaction, malaise
odpoved več organov, znižan indeks zmogljivosti, bolečina, edemi, bolečine v prsnem košu, stiskanje v prsnem košu, generaliziran edem, edem obraza, lokalno otekanje, lokaliziran edem, povečanje telesne mase, zgodnja sitost, občutek mraza, reakcija na mestu injiciranja, slabo počutje
multi-organ failureb,c, systemic inflammatory response syndromed, infusion related reaction
odpoved več organovb,c, sindrom sistemskega vnetnega odzivad, infuzijske reakcije
multi-pack
Skupna
multi-pack
Skupna pakiranja
Multi-pack: 12 (3 packs of 4) pre-filled pens of 0.5 ml solution.
Večje pakiranje: 12 (3 pakiranja po 4) napolnjenih injekcijskih peresnikov z 0,5 ml raztopine.
Multi-pack: 12 (3 packs of 4) pre-filled pens of 0.5 ml solution.
Večje pakiranje: 12 (3 škatle po 4) napolnjenih injekcijskih peresnikov z 0,5 ml raztopine.
Multi-pack: 12 (3 packs of 4) pre-filled syringes of 0.5 ml solution.
Večje pakiranje: 12 (3 škatle po 4) napolnjenih injekcijskih brizg z 0,5 ml raztopine.
Multi-pack: 4 pre-filled pens of 0.5 ml solution.
Večje pakiranje: 4 napolnjeni injekcijski peresniki z 0,5 ml raztopine.
Multi-pack: 4 pre-filled syringes of 0.5 ml solution.
Večje pakiranje: 4 napolnjene injekcijske brizge z 0,5 ml raztopine.
Multi-packs (perforated unit dose blister) containing 98 (2 packs of 49 x 1) tablets.
Skupna pakiranja (perforirani pretisni omoti za posamične odmerke) vsebujejo 98 tablet (2 škatli po 49 x 1 tableta).
Multi-packs containing 280 (20 packs of 14) tablets.
Skupna pakiranja vsebujejo po 280 tablet (20 škatel po 14 tablet).
Multi-packs containing 280 tablets (20 packs of 14)
Skupna pakiranja vsebujejo 280 tablet (20 pakiranj po 14 tablet).
Multi-packs containing 90 (3 packs of 30), 98 (2 packs of 49) or 280 (20 packs of 14) tablets.
Skupna pakiranja vsebujejo po 90 (3 škatle po 30 tablet), 98 (2 škatli po 49 tablet) ali 280 tablet (20 škatel po 14 tablet).
Multi-packs of 196 (2 packs of 98 modified-release tablets) – without blue box (for PVC/Aclar blister)
Multi pakiranje po 196 (2 zavoja po 98 tablet s prirejenim sproščanjem) – brez blue box-a (s PVC/Aclar pretisnimi omoti)
Multi-packs of unit dose (perforated unit dose blister) containing 98x1 tablet (2 packs of 49x1)
Skupna pakiranja z razdelki za enkratni odmerek (perforiran pretisni omot z razdelki za enkratni odmerek) vsebuje 98x1 tableto (2 pakiranji po 49x1 tableto).
Multicentre Trial N with CR = 34
Multicentrična študija N s CR = 34
Multicentre Trial N=40
Multicentrična raziskava N=40
Multicentric Castleman’s disease causes benign tumours (non-cancerous growths) to develop in the lymph nodes in the body.
Multicentrična Castlemanova bolezen povzroči, da se v bezgavkah po telesu razvijejo benigni tumorji (nerakaste tvorbe).
Multicentric means that the disease affects several lymph nodes as well as other organs in the body.
Multicentrična pomeni, da bolezen prizadene več bezgavk ter tudi druge organe v telesu.
multidose pen
peresniku
multidose pen
večodmernem peresniku
Multidose presentations must be for individual patient use only.
Liek s ukončenou platnosťou registrácie
multidose vial
viala (steklo);
Multidose vial (10 doses of 0.5 ml per vial)
večodmerna viala (10 odmerkov po 0,5 ml)
Multidose vial (10 doses of 0.5 ml)
Večodmerna viala (v viali je 10 odmerkov po 0,5 ml)
Multidose vial (5 ml)
Viala (5 ml) z več odmerki
Multidose vial EU/1/09/508/009
Večodmerna viala EU/1/09/508/009
Multidose vial: once opened, store for a maximum of 14 days at 20°C-25°C. Opened on: DD/MM/YY
Večodmerna viala: po odprtju shranjujte največ 14 dni pri 20 °C do 25 °C. Odprto dne: DD/MM/LL